{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:59:16Z","timestamp":1790362756717,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10147-026-03061-8","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T19:48:16Z","timestamp":1780170496000},"page":"2133-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Primary site- and metastasis-directed therapies in patients with metastatic prostate cancer: A narrative review"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6537-3068","authenticated-orcid":false,"given":"Takayuki","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Sumiyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Masui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rihito","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Mizowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"3061_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H et al (2023) First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol 9:635\u2013645","journal-title":"JAMA Oncol"},{"key":"3061_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","volume":"18","author":"MC Haffner","year":"2021","unstructured":"Haffner MC, Zwart W, Roudier MP et al (2021) Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol 18:79\u201392","journal-title":"Nat Rev Urol"},{"key":"3061_CR3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nature14347","volume":"520","author":"G Gundem","year":"2015","unstructured":"Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353\u2013357","journal-title":"Nature"},{"key":"3061_CR4","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","volume":"81","author":"Q Cheng","year":"2022","unstructured":"Cheng Q, Butler W, Zhou Y et al (2022) Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol 81:446\u2013455","journal-title":"Eur Urol"},{"key":"3061_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378\u2013382","journal-title":"Nat Rev Clin Oncol"},{"key":"3061_CR6","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.euo.2024.03.007","volume":"7","author":"I Tsuboi","year":"2024","unstructured":"Tsuboi I, Matsukawa A, Kardoust Parizi M et al (2024) A systematic review and meta-analysis of the impact of local therapies on local event suppression in metastatic hormone-sensitive prostate cancer. Eur Urol Oncol 7:1185\u20131194","journal-title":"Eur Urol Oncol"},{"key":"3061_CR7","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker CC, James ND, Brawley CD et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353\u20132366","journal-title":"Lancet"},{"key":"3061_CR8","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9 LMS, Hulshof MCCM, Vis AN et al (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur Urol 75:410\u2013418","journal-title":"Eur Urol"},{"key":"3061_CR9","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X et al (2024) Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet 404:2065\u20132076","journal-title":"Lancet"},{"key":"3061_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K et al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 36:446\u2013453","journal-title":"J Clin Oncol"},{"key":"3061_CR11","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6:650\u2013659","journal-title":"JAMA Oncol"},{"key":"3061_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang C, Sherry AD, Haymaker C et al (2023) Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial. JAMA Oncol 9:825\u2013834","journal-title":"JAMA Oncol"},{"key":"3061_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","volume":"88","author":"AD Sherry","year":"2025","unstructured":"Sherry AD, Siddiqui BA, Haymaker C et al (2025) Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial. Eur Urol 88:496\u2013509","journal-title":"Eur Urol"},{"key":"3061_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8\u201310","journal-title":"J Clin Oncol"},{"key":"3061_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","volume":"148","author":"Y Lievens","year":"2020","unstructured":"Lievens Y, Guckenberger M, Gomez D et al (2020) Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document. Radiother Oncol 148:157\u2013166","journal-title":"Radiother Oncol"},{"key":"3061_CR16","doi-asserted-by":"publisher","first-page":"202.e9","DOI":"10.1016\/j.urolonc.2015.01.022","volume":"33","author":"A Patrikidou","year":"2015","unstructured":"Patrikidou A, Brureau L, Casenave J et al (2015) Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol 33:202.e9\u201317","journal-title":"Urol Oncol"},{"key":"3061_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s10147-016-0993-x","volume":"21","author":"T Kobayashi","year":"2016","unstructured":"Kobayashi T, Kamba T, Terada N et al (2016) High incidence of urological complications in men dying from prostate cancer. Int J Clin Oncol 21:1150\u20131154","journal-title":"Int J Clin Oncol"},{"key":"3061_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1089\/jpm.2006.0185","volume":"10","author":"R Khafagy","year":"2007","unstructured":"Khafagy R, Shackley D, Samuel J et al (2007) Complications arising in the final year of life in men dying from advanced prostate cancer. J Palliat Med 10:705\u2013711","journal-title":"J Palliat Med"},{"key":"3061_CR19","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00520-012-1666-6","volume":"21","author":"BA Spencer","year":"2013","unstructured":"Spencer BA, Insel BJ, Hershman DL et al (2013) Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer. Support Care Cancer 21:1303\u20131311","journal-title":"Support Care Cancer"},{"key":"3061_CR20","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65:1058\u20131066","journal-title":"Eur Urol"},{"key":"3061_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2014.04.009","volume":"66","author":"C Gratzke","year":"2014","unstructured":"Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66:602\u2013603","journal-title":"Eur Urol"},{"key":"3061_CR22","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.juro.2015.02.084","volume":"194","author":"R Satkunasivam","year":"2015","unstructured":"Satkunasivam R, Kim AE, Desai M et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol 194:378\u2013385","journal-title":"J Urol"},{"key":"3061_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2017.03.020","volume":"72","author":"S-R Leyh-Bannurah","year":"2017","unstructured":"Leyh-Bannurah S-R, Gazdovich S, Bud\u00e4us L et al (2017) Local therapy improves survival in metastatic prostate cancer. Eur Urol 72:118\u2013124","journal-title":"Eur Urol"},{"key":"3061_CR24","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1200\/JCO.2016.67.4788","volume":"34","author":"CG Rusthoven","year":"2016","unstructured":"Rusthoven CG, Jones BL, Flaig TW et al (2016) Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol 34:2835\u20132842","journal-title":"J Clin Oncol"},{"key":"3061_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eururo.2016.04.031","volume":"72","author":"B L\u00f6ppenberg","year":"2017","unstructured":"L\u00f6ppenberg B, Dalela D, Karabon P et al (2017) The impact of local treatment on overall survival in patients with metastatic prostate cancer on diagnosis: a National Cancer Data Base analysis. Eur Urol 72:14\u201319","journal-title":"Eur Urol"},{"key":"3061_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett S, Boev\u00e9 LM, Ingleby FC et al (2019) Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur Urol 76:115\u2013124","journal-title":"Eur Urol"},{"key":"3061_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41391-022-00598-3","volume":"26","author":"EC Wang","year":"2023","unstructured":"Wang EC, Lee WR, Armstrong AJ (2023) Second generation antiandrogens androgen deprivation therapy radiation therapy definitive management high-risk prostate cancer. Prostate Cancer Prostatic Dis 26:30\u201340","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3061_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","volume":"86","author":"S Roy","year":"2024","unstructured":"Roy S, Fervaha G, Spratt DE et al (2024) Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur Urol 86:10\u201317","journal-title":"Eur Urol"},{"key":"3061_CR29","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/bco2.35","volume":"1","author":"N Terada","year":"2020","unstructured":"Terada N, Mizowaki T, Saito T et al (2020) Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. BJUI Compass 1:165\u2013173","journal-title":"BJUI Compass"},{"key":"3061_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/jjco\/hyaf157","volume":"56","author":"N Terada","year":"2026","unstructured":"Terada N, Nihei K, Aizawa R et al (2026) Protocol summary of a randomized controlled phase III trial for confirming the superiority of local radiotherapy for prostate cancer patients with high-volume metastasis sensitive to hormonal therapy: the JCOG2011 (HimeRT study). Jpn J Clin Oncol 56:104\u2013109","journal-title":"Jpn J Clin Oncol"},{"key":"3061_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","volume":"5","author":"B Dai","year":"2022","unstructured":"Dai B, Zhang S, Wan F-N et al (2022) Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur Urol Oncol 5:519\u2013525","journal-title":"Eur Urol Oncol"},{"key":"3061_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.09.4144","author":"M Graefen","year":"2025","unstructured":"Graefen M, Falkenbach F, Maurer T et al (2025) Best systemic therapy with or without radical prostatectomy in the management of men with oligometastatic prostate cancer: the RAMPP randomised controlled trial. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144","journal-title":"Eur Urol"},{"key":"3061_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran P, Wilson C, Rombach I et al (2022) Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial. BJU Int 130:43\u201353","journal-title":"BJU Int"},{"key":"3061_CR34","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(25)00658-8","volume":"27","author":"C Tang","year":"2026","unstructured":"Tang C, Sherry AD, Hwang H et al (2026) Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration. Lancet Oncol 27:181\u2013190","journal-title":"Lancet Oncol"},{"key":"3061_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J et al (2017) Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol 7:4\u201312","journal-title":"Pract Radiat Oncol"},{"key":"3061_CR36","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","volume":"21","author":"M Guckenberger","year":"2020","unstructured":"Guckenberger M, Lievens Y, Bouma AB et al (2020) Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol 21:e18\u2013e28","journal-title":"Lancet Oncol"},{"key":"3061_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.urolonc.2011.02.023","volume":"31","author":"A Muacevic","year":"2013","unstructured":"Muacevic A, Kufeld M, Rist C et al (2013) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases of prostate cancer. Urol Oncol 31:455\u2013460","journal-title":"Urol Oncol"},{"key":"3061_CR38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fonc.2012.00172","volume":"2","author":"KA Ahmed","year":"2012","unstructured":"Ahmed KA, Barney BM, Davis BJ et al (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 2:215","journal-title":"Front Oncol"},{"key":"3061_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-135","volume":"9","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker K, De Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 9:135","journal-title":"Radiat Oncol"},{"key":"3061_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.eururo.2018.06.004","volume":"74","author":"S Siva","year":"2018","unstructured":"Siva S, Bressel M, Murphy DG et al (2018) Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol 74:455\u2013462","journal-title":"Eur Urol"},{"key":"3061_CR41","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 393:2051\u20132058","journal-title":"Lancet"},{"key":"3061_CR42","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38:2830\u20132838","journal-title":"J Clin Oncol"},{"key":"3061_CR43","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Van der Eecken K, Sutera P et al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J Clin Oncol 40:3377\u20133382","journal-title":"J Clin Oncol"},{"key":"3061_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso G, Corrao G, Zaffaroni M et al (2025) ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol 26:300\u2013311","journal-title":"Lancet Oncol"},{"key":"3061_CR45","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","volume":"85","author":"J Nikitas","year":"2024","unstructured":"Nikitas J, Rettig M, Shen J et al (2024) Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial. Eur Urol 85:517\u2013520","journal-title":"Eur Urol"},{"key":"3061_CR46","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO-25-00131","volume":"43","author":"JH Wang","year":"2025","unstructured":"Wang JH, Sherry AD, Bazyar S et al (2025) Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial. J Clin Oncol 43:2059\u20132068","journal-title":"J Clin Oncol"},{"key":"3061_CR47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","volume":"26","author":"P Ost","year":"2025","unstructured":"Ost P, Siva S, Brabrand S et al (2025) Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial. Lancet Oncol 26:695\u2013706","journal-title":"Lancet Oncol"},{"key":"3061_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","volume":"80","author":"S Supiot","year":"2021","unstructured":"Supiot S, Vaugier L, Pasquier D et al (2021) OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer. Eur Urol 80:405\u2013414","journal-title":"Eur Urol"},{"key":"3061_CR49","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eururo.2024.02.013","volume":"87","author":"L Vaugier","year":"2025","unstructured":"Vaugier L, Morvan C, Pasquier D et al (2025) Long-term outcomes and patterns of relapse following high-dose elective salvage radiotherapy and hormone therapy in oligorecurrent pelvic nodes in prostate cancer: OLIGOPELVIS (GETUG-P07). Eur Urol 87:73\u201376","journal-title":"Eur Urol"},{"key":"3061_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini E, Gray KP, Xie W et al (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889\u2013895","journal-title":"Prostate"},{"key":"3061_CR51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.urology.2016.10.044","volume":"102","author":"MJ O\u2019Shaughnessy","year":"2017","unstructured":"O\u2019Shaughnessy MJ, McBride SM, Vargas HA et al (2017) A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer. Urology 102:164\u2013172","journal-title":"Urology"},{"key":"3061_CR52","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/pros.23757","volume":"79","author":"H Tsumura","year":"2019","unstructured":"Tsumura H, Ishiyama H, Tabata K-I et al (2019) Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: a retrospective cohort study. Prostate 79:506\u2013514","journal-title":"Prostate"},{"key":"3061_CR53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/iju.14567","volume":"28","author":"R Aizawa","year":"2021","unstructured":"Aizawa R, Takayama K, Nakamura K et al (2021) Long-term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: a combination of prostate-targeted treatment and metastasis-directed therapy. Int J Urol 28:749\u2013755","journal-title":"Int J Urol"},{"key":"3061_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","volume":"86","author":"NG Nickols","year":"2024","unstructured":"Nickols NG, Tsai S, Kane N et al (2024) Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer. Eur Urol 86:190\u2013193","journal-title":"Eur Urol"},{"key":"3061_CR55","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"3061_CR56","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1056\/NEJM198506203122504","volume":"312","author":"AR Feinstein","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK (1985) The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 312:1604\u20131608","journal-title":"N Engl J Med"},{"key":"3061_CR57","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.21873\/anticanres.17623","volume":"45","author":"R Aizawa","year":"2025","unstructured":"Aizawa R, Ogata T, Goto T et al (2025) Clinical outcomes of metastasis-directed therapy for oligo-metastatic prostate cancer diagnosed using PSMA-PET\/CT or whole-body MRI. Anticancer Res 45:2515\u20132525","journal-title":"Anticancer Res"},{"key":"3061_CR58","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.euo.2020.06.012","volume":"4","author":"M Anttinen","year":"2021","unstructured":"Anttinen M, Ettala O, Malaspina S et al (2021) A prospective comparison of 18F-prostate-specific membrane antigen-1007 positron emission tomography computed tomography, whole-body 1.5 T magnetic resonance imaging with diffusion-weighted imaging, and single-photon emission computed tomography\/computed tomography with traditional imaging in primary distant metastasis staging of prostate cancer (PROSTAGE). Eur Urol Oncol 4:635\u2013644","journal-title":"Eur Urol Oncol"},{"key":"3061_CR59","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00330-018-5682-x","volume":"29","author":"E Dyrberg","year":"2019","unstructured":"Dyrberg E, Hendel HW, Huynh THV et al (2019) 68Ga-PSMA-PET\/CT in comparison with 18F-fluoride-PET\/CT and whole-body MRI for the detection of bone metastases in patients with prostate cancer: a prospective diagnostic accuracy study. Eur Radiol 29:1221\u20131230","journal-title":"Eur Radiol"},{"key":"3061_CR60","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s10147-026-02958-8","volume":"31","author":"S Murata","year":"2026","unstructured":"Murata S, Moribata Y, Akamatsu S et al (2026) 18F-PSMA-PET\/CT in comparison with whole-body MRI and combination of conventional CT and bone scintigraphy for detection of recurrent disease in prostate cancer patients with rising PSA levels after initial definitive treatment. Int J Clin Oncol 31:484\u2013493","journal-title":"Int J Clin Oncol"},{"key":"3061_CR61","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","volume":"176","author":"T Zilli","year":"2022","unstructured":"Zilli T, Achard V, Dal Pra A et al (2022) Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol 176:199\u2013207","journal-title":"Radiother Oncol"},{"key":"3061_CR62","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/386804a0","volume":"386","author":"SK Sharan","year":"1997","unstructured":"Sharan SK, Morimatsu M, Albrecht U et al (1997) Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature 386:804\u2013810","journal-title":"Nature"},{"key":"3061_CR63","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3892\/or.2017.5407","volume":"37","author":"A Baert","year":"2017","unstructured":"Baert A, Depuydt J, Van Maerken T et al (2017) Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncol Rep 37:1379\u20131386","journal-title":"Oncol Rep"},{"key":"3061_CR64","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.euo.2022.02.002","volume":"5","author":"J Pan","year":"2022","unstructured":"Pan J, Wei Y, Zhang T et al (2022) Stereotactic radiotherapy for lesions detected via 68Ga-prostate-specific membrane antigen and 18F-fluorodexyglucose positron emission tomography\/computed tomography in patients with nonmetastatic prostate cancer with early prostate-specific antigen progression on androgen deprivation therapy: a prospective single-center study. Eur Urol Oncol 5:420\u2013427","journal-title":"Eur Urol Oncol"},{"key":"3061_CR65","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1200\/JCO.23.00985","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini G, Allegra AG, Detti B et al (2023) Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO). J Clin Oncol 41:5561\u20135568","journal-title":"J Clin Oncol"},{"key":"3061_CR66","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S1470-2045(25)00351-1","volume":"26","author":"T Niazi","year":"2025","unstructured":"Niazi T, Saad F, Tisseverasinghe S et al (2025) Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 26:1158\u20131167","journal-title":"Lancet Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03061-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03061-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:02:56Z","timestamp":1790359376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03061-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":66,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3061"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03061-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TM has received honoraria from Varian Medical Systems, BrainLab, Hitachi High-Tech, Elekta, and Novartis and grants from Varian Medical Systems, BrainLab, Hitachi High-Tech, and Novartis and a scholarship from Hitachi High-Tech. TG, KM, TS, YK, KM, TO, RA, AS, RS, and TK declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}